---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Access and coverage questions"
description: "Access and coverage questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing, Cost and coverage, Prior authorization, Access support, and Patient support. Questions: What are the NDC numbers and pack sizes for Ubrelvy? Is there a Ubrelvy copay card (savings card)? How much do commercially insured patients pay for Ubrelvy with the savings card? Can Medicare patients use the Ubrelvy savings card? 8 further questions follow. 12 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Access and coverage questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Access and billing

<a id="ubrelvy-ndc"></a>

### What are the NDC numbers and pack sizes for Ubrelvy?

> “UBRELVY 50 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed 
> with “U50” on one side in unit-dose packets (each packet contains 1 tablet): 
> • Box of 10 Packets, NDC: 0023-6498-10 
> • Box of 16 Packets, NDC: 0023-6498-16 
> • Box of 30 Packets, NDC: 0023-6498-30 
> UBRELVY 100 mg is supplied as white to off-white capsule-shaped, biconvex tablets debossed 
> with “U100” on one side in unit-dose packets (each packet contains 1 tablet):  
> • Box of 10 Packets, NDC: 0023-6501-10 
> • Box of 16 Packets, NDC: 0023-6501-16 
> • Box of 30 Packets, NDC: 0023-6501-30”

Source: [UBRELVY: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=14)

## Cost and coverage

<a id="ubrelvy-savings-card"></a>

### Is there a Ubrelvy copay card (savings card)?

> “WITH THE UBRELVY COMPLETE SAVINGS CARD, ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS $0* PER MONTH
>
> CARD SAVINGS ARE APPLIED TO PATIENTS’ OUT-OF-POCKET COSTS
>
> Patients can sign up for the UBRELVY Complete Savings Card by:
>
> Visiting UBRELVY.com/savings
> Texting<sup>†</sup> UBRELVY to 48764
>
> If you or your patients have questions about the UBRELVY Complete Savings Program, call 1.844.4.UBRELVY.”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=WITH%20THE%20UBRELVY%20COMPLETE%20SAVINGS,Complete%20Savings%20Program%2C%20call%201.844.4.UBRELVY.)

> “*Eligibility: Available to patients with commercial insurance coverage for UBRELVY who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit UBRELVY.com/savings-terms or call 1-844-482-7358 for additional information.”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=%2AEligibility%3A%20Available%20to%20patients%20with,call%201%2D844%2D482%2D7358%20for%20additional%20information.)

Note: Program terms as shown on the savings page of the Ubrelvy HCP site, captured November 2026. That page directs readers to UBRELVY.com/savings-terms or 1-844-482-7358 for the full terms; the access and support page of the same site directs them to UBRELVYsavingscard.com or 1-844-577-6239.

<a id="ubrelvy-cost-commercial"></a>

### How much do commercially insured patients pay for Ubrelvy with the savings card?

> “WITH THE UBRELVY COMPLETE SAVINGS CARD, ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS $0* PER MONTH”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=WITH%20THE%20UBRELVY%20COMPLETE%20SAVINGS,LITTLE%20AS%20%240%2A%20PER%20MONTH)

> “95<sup>%</sup>
>
>
>
> OF ELIGIBLE COMMERCIALLY INSURED PATIENTS PAY $0 FOR UBRELVY WITH THEIR UBRELVY COMPLETE SAVINGS CARD<sup>1‡</sup>”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=OF%20ELIGIBLE%20COMMERCIALLY%20INSURED%20PATIENTS,WITH%20THEIR%20UBRELVY%20COMPLETE%20SAVINGS)

> “<sup>‡</sup>Data on file. AbbVie Inc. (Savings card redemption data as of January 2024–December 2024 and subject to change.)”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=on%20file.%20AbbVie%20Inc.%20%28Savings,2024%20and%20subject%20to%20change.%29)

> “95% of commercially insured patients pay $0  
> with their UBRELVY Complete Savings Card<sup>1‡</sup>”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 5, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=5)

> “<sup>‡</sup>Data on file. AbbVie Inc. (Savings Card redemption data as of January 2025-December 2025 and subject to change.)”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 5, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=5)

> “*Eligibility: Available to patients with commercial insurance coverage for UBRELVY who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply.”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=%2AEligibility%3A%20Available%20to%20patients%20with,including%20monthly%20maximums%2C%20may%20apply.)

Note: The savings page of the Ubrelvy HCP site gives the 95% figure for savings card redemptions in 2024; the prior authorization guide that the resources page links gives 95% for 2025. The savings card is limited to commercially insured patients. The captured pages state no list price or cost without insurance.

<a id="ubrelvy-medicare"></a>

### Can Medicare patients use the Ubrelvy savings card?

> “*Eligibility: Available to patients with commercial insurance coverage for UBRELVY who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law.”

Source: [UBRELVY: Savings and Support | UBRELVY® (ubrogepant) | HCP, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support#:~:text=%2AEligibility%3A%20Available%20to%20patients%20with,or%20where%20prohibited%20by%20law.)

<a id="ubrelvy-triptan-challenge"></a>

### What is the Ubrelvy Challenge offer for patients taking an oral triptan?

> “FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS TAKING AN ORAL TRIPTAN
>
>
>
> START YOUR PATIENTS ON UBRELVY WITH THE UBRELVY CHALLENGE. IF THEY CHOOSE TO REFILL THEIR TRIPTAN, THE NEXT TRIPTAN FILL IS ON US.<sup>‡</sup>”

Source: [UBRELVY: Savings and Support | UBRELVY® (ubrogepant) | HCP, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support#:~:text=FOR%20ELIGIBLE%20COMMERCIALLY%20INSURED%20PATIENTS,NEXT%20TRIPTAN%20FILL%20IS%20ON)

> “<sup>‡</sup>Offer not available to patients enrolled in Medicare, Medicaid, or any other federal or state healthcare programs. Restrictions, including savings maximums, apply. Patient out-of-pocket expense will vary depending on insurance coverage. UBRELVY coupon becomes valid upon activation of offer. Oral triptan medication coupon becomes valid two (2) weeks from activation of offer and expires six (6) weeks from activation of offer. For full Terms and Conditions, visit ubrelvy.com/challenge-terms or call 1-844-577-6239 for more information.”

Source: [UBRELVY: Savings and Support | UBRELVY® (ubrogepant) | HCP, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support#:~:text=not%20available%20to%20patients%20enrolled,call%201%2D844%2D577%2D6239%20for%20more%20information.)

> “No head-to-head studies have been conducted between UBRELVY and triptans; therefore, no conclusions regarding safety or efficacy can be drawn.”

Source: [UBRELVY: Savings and Support | UBRELVY® (ubrogepant) | HCP, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support#:~:text=No%20head%2Dto%2Dhead%20studies%20have%20been,or%20efficacy%20can%20be%20drawn.)

Note: Offer terms as shown on the access and support page of the Ubrelvy HCP site, captured November 2026.

<a id="ubrelvy-insurance-coverage"></a>

### How widely is Ubrelvy covered by commercial insurance?

> “≥97% of nationally commercially 
> insured lives are covered for  
> QULIPTA® and UBRELVY®*”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 7, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=7)

> “*Managed Markets Insight & Technology, LLCTM, a trademark of MMIT. Data as of December 2025 and subject to change.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 7, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=7)

> “56% of commercially insured lives are unrestricted or require 0 or 1 prior therapy to access UBRELVY<sup>8‡§</sup>”

Source: [UBRELVY: Acute Migraine Treatment, captured 2026-11-14](https://www.ubrelvyhcp.com/#:~:text=56%25%20of%20commercially%20insured%20lives,1%20prior%20therapy%20to%20access)

> “Managed Markets Insight & Technology, LLC<sup>TM</sup>, a trademark of MMIT. Data as of January 2025 and subject to change.”

Source: [UBRELVY: Acute Migraine Treatment, captured 2026-11-14](https://www.ubrelvyhcp.com/#:~:text=Managed%20Markets%20Insight%20%26%20Technology%2C,2025%20and%20subject%20to%20change.)

> “Unrestricted implies no step edit.”

Source: [UBRELVY: Acute Migraine Treatment, captured 2026-11-14](https://www.ubrelvyhcp.com/#:~:text=Unrestricted%20implies%20no%20step%20edit.)

> “Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.”

Source: [UBRELVY: Acute Migraine Treatment, captured 2026-11-14](https://www.ubrelvyhcp.com/#:~:text=Data%20are%20not%20a%20guarantee,not%20imply%20efficacy%20or%20safety.)

Note: The 97% figure is from the prior authorization guide that the resources page of the Ubrelvy HCP site links; the guide states it for Qulipta and Ubrelvy together, with MMIT data as of December 2025. The 56% figure is from the home page of the Ubrelvy HCP site, with MMIT data as of January 2025; the prior authorization guide (dated 05/26) repeats the 56% figure, citing AbbVie data on file. The captured pages state no Medicare Part D coverage figure, and the savings card excludes Medicare patients.

## Prior authorization

<a id="ubrelvy-prior-authorization"></a>

### What do insurers require for Ubrelvy prior authorization?

> “Indicated for the acute treatment of 
> migraine with or without aura in adults
> Payers may have varying requirements for 
> patients, which may include:
> •  Being 18 years of age or older
> •  Having a diagnosis of migraine”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

> “Many payers do not require additional clinical tests to support PA criteria.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

> “Upon PA approval, reauthorization may 
> be required after 12 months.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

Note: From the prior authorization guide for Qulipta and Ubrelvy that the resources page of the Ubrelvy HCP site links. The statement on clinical tests is made for both products.

<a id="ubrelvy-step-therapy"></a>

### Do insurers require trying triptans before Ubrelvy (step therapy)?

> “Treatment trial, contraindication, or 
> intolerance of 1 to 2 triptans, such as: 
> •  IMITREX® (sumatriptan) 
> •  RELPAX® (eletriptan) 
> •  MAXALT® (rizatriptan)
> •  ZOMIG® (zolmitriptan)”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

> “<sup>*</sup>The examples in this section do not represent a complete list of medications that may be required for step therapy by plan administrators.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

Note: From the prior authorization guide for Qulipta and Ubrelvy that the resources page of the Ubrelvy HCP site links. The guide lists these examples under step therapy requirements for Ubrelvy.

<a id="ubrelvy-quantity-limits"></a>

### Do insurance plans limit how many Ubrelvy tablets can be prescribed?

> “Some payers may have quantity limits 
> for UBRELVY®, allowing only a set number of 
> tablets to be prescribed over a predefined 
> time period.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 4, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=4)

Note: From the prior authorization guide for Qulipta and Ubrelvy that the resources page of the Ubrelvy HCP site links.

<a id="ubrelvy-prior-authorization-denial"></a>

### Why are Ubrelvy prior authorizations commonly denied?

> “Most common reasons for PA denial<sup>1</sup>
> •  The patient hasn’t stepped through 
>  the required medications	
> •  Questions regarding necessity
> •  Administrative errors
> •  Incomplete information
> •  The requested drug isn’t covered by the 
> patient’s formulary”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 6, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=6)

> “If you have any questions about a denied PA, reach out to your sales 
> representative to put you in contact with your Field Reimbursement Manager.”

Source: [UBRELVY: prior-authorization-guide-digital.pdf, page 6, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/prior-authorization-guide-digital.pdf#page=6)

Note: From the prior authorization guide for Qulipta and Ubrelvy that the resources page of the Ubrelvy HCP site links. The guide states these reasons for Qulipta and Ubrelvy together and does not separate them by product.

## Access support

<a id="ubrelvy-reimbursement-support"></a>

### What reimbursement and appeals support does AbbVie offer for Ubrelvy?

> “Field Reimbursement Managers can help educate on payer prior authorization, billing questions, and appeals processes to help determine the best access option for your patient.
>
> They can answer your access-related questions in-office or over the phone.”

Source: [UBRELVY: Access Patient Resources & Support, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/resources#:~:text=Field%20Reimbursement%20Managers%20can%20help,in%2Doffice%20or%20over%20the%20phone.)

> “Download Sample Templates and PA Guide
>
> SAMPLE APPEALS LETTER
>
>
>
> DOWNLOAD
>
> MEDICAL NECESSITY SAMPLE LETTER
>
>
>
> DOWNLOAD
>
> FORMULARY EXCEPTION LETTER
>
>
>
> DOWNLOAD
>
> PRIOR AUTHORIZATION GUIDE
>
>
>
> DOWNLOAD
>
> TIERED EXCEPTION SAMPLE LETTER”

Source: [UBRELVY: Access Patient Resources & Support, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/resources#:~:text=Download%20Sample%20Templates%20and%20PA,TIERED%20EXCEPTION%20SAMPLE%20LETTER)

> “For access and reimbursement questions, contact your Field Reimbursement Manager”

Source: [UBRELVY: UBRELVY® Savings & Coverage, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/savings#:~:text=For%20access%20and%20reimbursement%20questions%2C%20contact%20your%20Field%20Reimbursement%20Manager)

## Patient support

<a id="ubrelvy-samples"></a>

### Can prescribers order Ubrelvy samples?

> “GET SAMPLES AND SUPPORT
>
> GET PATIENTS STARTED WITH
> SAMPLES OF UBRELVY
>
>
>
> ORDER SAMPLES”

Source: [UBRELVY: Access Patient Resources & Support, captured 2026-11-14](https://www.ubrelvyhcp.com/access-and-support/resources#:~:text=GET%20SAMPLES%20AND%20SUPPORT,ORDER%20SAMPLES)

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
